Ulcerative Colitis

About IMS IMS is a novel analogue of inosine, an endogenous purine and a natural by-product of adenosine metabolism.

Inotek discovered the unique, anti-inflammatory properties of inosine although inosine, itself, is not a candidate for drug development due to its rapid metabolism.

IMS was specifically developed to both take advantage of the anti-inflammatory properties of inosine and to avoid its metabolic pathway.

In this regard, IMS represents a potentially exciting and novel approach to inflammatory bowel disease and many other chronic inflammatory conditions.

About Inotek Pharmaceuticals Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a private, high-growth, development-stage pharmaceutical company.

Inotek has two products in clinical development and five other products in pre-clinical development targeting oncology, cardiovascular, and inflammatory diseases.

The Company is pursuing indications in hospital cardiovascular markets as well as specialty care markets including dermatology, gastroenterology and oncology.

All of Inotek's technologies were discovered and developed by Inotek researchers.

The Company currently has approximately 120 employees, based in its headquarters and main laboratories in Beverly, Massachusetts and its clinical operations and GMP manufacturing facilities in Israel.

The Company's other lead clinical program is focused on the development of pot...

Read more...